Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.2513 -0.0987 (-28.20%)
Streaming Delayed Price Updated: 9:33 AM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,839
Open 0.3589
Bid (Size) 0.2700 (300)
Ask (Size) 0.4666 (100)
Prev. Close 0.3500
Today's Range 0.2513 - 0.4145
52wk Range 0.0525 - 1.110
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-16.1%
-16.1%
1 Month
-52.0%
-52.0%
3 Month
+109.4%
+109.4%
6 Month
+81.3%
+81.3%
1 Year
-65.1%
-65.1%

More News

Read More
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
From bioAffinity Technologies, Inc.
Via Business Wire
U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
From bioAffinity Technologies
Via Business Wire
bioAffinity Technologies Appoints New Members to Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Second Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
From bioAffinity Technologies, Inc.
Via Business Wire
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
From bioAffinity Technologies, Inc.
Via Business Wire

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Warrant publicly traded?
Yes, bioAffinity Technologies, Inc. - Warrant is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Warrant trade on?
bioAffinity Technologies, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Warrant?
The ticker symbol for bioAffinity Technologies, Inc. - Warrant is BIAFW on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Warrant?
The current price of bioAffinity Technologies, Inc. - Warrant is 0.2513
When was bioAffinity Technologies, Inc. - Warrant last traded?
The last trade of bioAffinity Technologies, Inc. - Warrant was at 11/07/25 09:33 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.